Direct inhibition of oncogenic RAS has emerged as a clinically active therapeutic strategy for RAS-addicted cancers, including pancreatic ductal adenocarcinoma (PDAC). However, resistance is likely to limit the durability of therapeutic response, motivating combination strategies that target adaptive survival mechani...
Joshua H. Choe, Kyle J. Seamon, Julien Dilly et al.· Cancer Research· 0 citations
Solid tumors evade immunotherapy because of immunosuppressive microenvironments that limit immune cell persistence and function. Although interleukin-12 (IL-12) potently activates antitumor immunity, its clinical use has been constrained by systemic toxicity. Here we engineered a CAR natural killer (NK) cell platform t...
Mubin Tarannum, K. Dinh, Mila Stanojevic et al.· Cancer Discovery· 0 citations
Recent studies have identified a high prevalence of low grade pancreatic intraepithelial neoplasia (PanIN) in the pancreata of healthy adults. This study aimed to characterize the transcriptomic landscape of human PanINs at single cell resolution, with the goal of identifying hallmarks of initiation and progressi...
C. Nguyen, Anders W. Ohman, Winston R. Becker et al.· Cancer Research· 0 citations
LIME bridged effector and tumor cells, induced transcriptional programs of T cell activation, metabolism and proliferation, and enhanced cytotoxicity across cancer cell lines and patient-derived organoids, establishing LIME as a versatile living therapeutic platform for programmable, tumor-restricted immune orchestrati...
Shao-Bo Yang, Anna Clara Bader, S. Sendker et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.